FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037276343> ?p ?o ?g. }

• W2037276343 endingPage "5053" @default.
• W2037276343 startingPage "5047" @default.
• W2037276343 abstract "ABSTRACT Botulinum neurotoxin A is a category A bioterrorism agent. Current antitoxin therapies are scarce and produce adverse reactions. XOMA 3AB consists of 3 IgG1 monoclonal antibodies (MAbs), each with a distinct human or humanized variable region, which bind to distinct epitopes on botulinum neurotoxin serotype A. This first-in-human study evaluated the safety and pharmacokinetics (PK) of escalating doses of XOMA 3AB administered intravenously (i.v.) to healthy adults. In this double-blind placebo-controlled dose escalation study, 3 cohorts of 8 healthy subjects received a single intravenous dose of XOMA 3AB or placebo at a 3:1 ratio. Follow-up examinations included physical examinations, hematology and chemistry blood tests, electrocardiograms, and pharmacokinetics. Pharmacokinetic parameters were estimated using noncompartmental methods. There were no infusion discontinuations or hypersensitivity reactions. Two or more subjects experienced headache, hyperglycemia, or anemia; none was dose related. All adverse events (AEs) were mild to moderate except for an episode of exercise-induced elevation of a subject's creatine phosphokinase (CPK) level, unrelated to XOMA 3AB. Concentration-time plots demonstrated a peak in MAb concentrations 1 to 2 h after completion of the infusion, after which the levels declined in a biexponential decay pattern for all analytes. For each MAb, the maximum concentration of drug in serum ( C max ) and the area under the concentration-time curve from 0 to infinity (AUC inf ) increased as the dose increased. Clearance of the humanized mouse MAb was more rapid than that of the two fully human MAbs, particularly at the lowest dose. None of the MAbs was immunogenic. At the doses administered, XOMA 3AB was well tolerated. These safety findings support further investigation of XOMA 3AB as a potential agent for botulism treatment and postexposure prophylaxis. (This study has been registered at ClinicalTrials.gov under registration no. NCT01357213.)" @default.
• W2037276343 created "2016-06-24" @default.
• W2037276343 creator A5000040521 @default.
• W2037276343 creator A5011939176 @default.
• W2037276343 creator A5027507914 @default.
• W2037276343 creator A5028882336 @default.
• W2037276343 creator A5032633622 @default.
• W2037276343 creator A5045625987 @default.
• W2037276343 creator A5046800487 @default.
• W2037276343 creator A5053567182 @default.
• W2037276343 creator A5065436034 @default.
• W2037276343 creator A5066660914 @default.
• W2037276343 date "2014-09-01" @default.
• W2037276343 modified "2023-09-25" @default.
• W2037276343 title "Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A" @default.
• W2037276343 cites W1606159008 @default.
• W2037276343 cites W2000966089 @default.
• W2037276343 cites W2013757167 @default.
• W2037276343 cites W2027872729 @default.
• W2037276343 cites W2040721469 @default.
• W2037276343 cites W2040806175 @default.
• W2037276343 cites W2045061466 @default.
• W2037276343 cites W2054806862 @default.
• W2037276343 cites W2081769761 @default.
• W2037276343 cites W2104360426 @default.
• W2037276343 cites W2106861685 @default.
• W2037276343 cites W2119983056 @default.
• W2037276343 cites W2126213235 @default.
• W2037276343 cites W2137889830 @default.
• W2037276343 cites W4235353622 @default.
• W2037276343 doi "https://doi.org/10.1128/aac.02830-14" @default.
• W2037276343 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4135817" @default.
• W2037276343 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24913160" @default.
• W2037276343 hasPublicationYear "2014" @default.
• W2037276343 type Work @default.
• W2037276343 sameAs 2037276343 @default.
• W2037276343 citedByCount "48" @default.
• W2037276343 countsByYear W20372763432015 @default.
• W2037276343 countsByYear W20372763432016 @default.
• W2037276343 countsByYear W20372763432017 @default.
• W2037276343 countsByYear W20372763432018 @default.
• W2037276343 countsByYear W20372763432019 @default.
• W2037276343 countsByYear W20372763432020 @default.
• W2037276343 countsByYear W20372763432021 @default.
• W2037276343 countsByYear W20372763432022 @default.
• W2037276343 countsByYear W20372763432023 @default.
• W2037276343 crossrefType "journal-article" @default.
• W2037276343 hasAuthorship W2037276343A5000040521 @default.
• W2037276343 hasAuthorship W2037276343A5011939176 @default.
• W2037276343 hasAuthorship W2037276343A5027507914 @default.
• W2037276343 hasAuthorship W2037276343A5028882336 @default.
• W2037276343 hasAuthorship W2037276343A5032633622 @default.
• W2037276343 hasAuthorship W2037276343A5045625987 @default.
• W2037276343 hasAuthorship W2037276343A5046800487 @default.
• W2037276343 hasAuthorship W2037276343A5053567182 @default.
• W2037276343 hasAuthorship W2037276343A5065436034 @default.
• W2037276343 hasAuthorship W2037276343A5066660914 @default.
• W2037276343 hasBestOaLocation W20372763431 @default.
• W2037276343 hasConcept C112705442 @default.
• W2037276343 hasConcept C126322002 @default.
• W2037276343 hasConcept C142724271 @default.
• W2037276343 hasConcept C159654299 @default.
• W2037276343 hasConcept C197934379 @default.
• W2037276343 hasConcept C203014093 @default.
• W2037276343 hasConcept C204787440 @default.
• W2037276343 hasConcept C22979827 @default.
• W2037276343 hasConcept C27081682 @default.
• W2037276343 hasConcept C2777288759 @default.
• W2037276343 hasConcept C542903549 @default.
• W2037276343 hasConcept C71924100 @default.
• W2037276343 hasConcept C98274493 @default.
• W2037276343 hasConceptScore W2037276343C112705442 @default.
• W2037276343 hasConceptScore W2037276343C126322002 @default.
• W2037276343 hasConceptScore W2037276343C142724271 @default.
• W2037276343 hasConceptScore W2037276343C159654299 @default.
• W2037276343 hasConceptScore W2037276343C197934379 @default.
• W2037276343 hasConceptScore W2037276343C203014093 @default.
• W2037276343 hasConceptScore W2037276343C204787440 @default.
• W2037276343 hasConceptScore W2037276343C22979827 @default.
• W2037276343 hasConceptScore W2037276343C27081682 @default.
• W2037276343 hasConceptScore W2037276343C2777288759 @default.
• W2037276343 hasConceptScore W2037276343C542903549 @default.
• W2037276343 hasConceptScore W2037276343C71924100 @default.
• W2037276343 hasConceptScore W2037276343C98274493 @default.
• W2037276343 hasIssue "9" @default.
• W2037276343 hasLocation W20372763431 @default.
• W2037276343 hasLocation W20372763432 @default.
• W2037276343 hasLocation W20372763433 @default.
• W2037276343 hasLocation W20372763434 @default.
• W2037276343 hasLocation W20372763435 @default.
• W2037276343 hasOpenAccess W2037276343 @default.
• W2037276343 hasPrimaryLocation W20372763431 @default.
• W2037276343 hasRelatedWork W2051764329 @default.
• W2037276343 hasRelatedWork W2064759457 @default.
• W2037276343 hasRelatedWork W2370929226 @default.
• W2037276343 hasRelatedWork W2379280247 @default.
• W2037276343 hasRelatedWork W2766550598 @default.
• W2037276343 hasRelatedWork W2942467058 @default.

• next